CALQUENCE 100 mg/1
Acalabrutinib · CAPSULE, GELATIN COATED · AstraZeneca Pharmaceuticals LP
CALQUENCE is a capsule, gelatin coated containing acalabrutinib at 100 mg/1, taken oral. Manufactured by AstraZeneca Pharmaceuticals LP.
Key Facts
- Brand Name
- CALQUENCE
- Generic Name
- Acalabrutinib
- NDC Code (Product)
0310-0512- Manufacturer
- AstraZeneca Pharmaceuticals LP
- Strength
- 100 mg/1
- Dosage Form
- CAPSULE, GELATIN COATED
- Route
- ORAL
- Marketing Status
- Application #
- NDA210259
- Drug Class
- Kinase Inhibitor [EPC]
- Marketing Start
- 10/31/2017
Recall History
No Recall HistorySide Effects Reported to FDA
FDA FAERS database · These are reported events, not confirmed side effects
Frequently Asked Questions
What is CALQUENCE used for?
CALQUENCE contains Acalabrutinib. It is a capsule, gelatin coated taken oral. Consult your doctor for specific uses.
Is CALQUENCE a controlled substance?
CALQUENCE is not classified as a controlled substance by the DEA.
What is the generic name for CALQUENCE?
The generic name for CALQUENCE is Acalabrutinib. There are no other listed brand versions of Acalabrutinib.
What is the NDC code for CALQUENCE 100 mg/1?
The NDC (National Drug Code) for CALQUENCE 100 mg/1 is 0310-0512, listed by AstraZeneca Pharmaceuticals LP.
Product NDC
0310-0512
Other CALQUENCE Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)